Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine ; volume:20 ; number:1 ; day:12 ; month:10 ; year:2020 ; pages:1-13 ; date:12.2020
BMC cancer ; 20, Heft 1 (12.10.2020), 1-13, 12.2020
- Creator
-
Nishi, Rie
Shigemi, Hiroko
Negoro, Eiju
Okura, Miyuki
Hosono, Naoko
Yamauchi, Takahiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-07469-x
- URN
-
urn:nbn:de:101:1-2020112721261916893192
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nishi, Rie
- Shigemi, Hiroko
- Negoro, Eiju
- Okura, Miyuki
- Hosono, Naoko
- Yamauchi, Takahiro
- SpringerLink (Online service)
Other Objects (12)
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4